0000000000144613

AUTHOR

Damiano Baroncini

showing 4 related works from this author

Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.

2022

Background: Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available. Objectives: To compare diagnostic performances of two different data-driven SPMS definitions. Methods: Data-driven SPMS definitions based on a version of Lorscheider’s algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist’s definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC). Results: A cohort of 10,240 MS patients wi…

Multiple SclerosisMultiple Sclerosis Chronic ProgressiveMultiple sclerosisMultiple Sclerosis Relapsing-RemittingNeurologybig dataArea Under Curvedata-driven algorithmdisease registrysecondary progressiveHumansSettore MED/26 - NeurologiaNeurology (clinical)prognosisMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis

2021

Importance Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging. Objective To evaluate changes in the prognosis of POMS over time in association with changes in therapeutic and managing standards. Design, Setting, and Participants Retrospective, multicenter, observational study. Data were extracted and collected in May 2019 from the Italian MS Registry, a digital database including more than 59 000 patients. Inclusion criteria were…

MaleRegistriePediatricsAdolescent; Adult; Age of Onset; Aged; Child; Child Preschool; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Registries; Retrospective Studies; Risk Factors; Young Adult; Disabled Persons; Disease ProgressionRisk of Disability0302 clinical medicineRisk FactorsRetrospective StudieMultiple Sclerosi030212 general & internal medicineRegistriesAge of OnsetChildOriginal InvestigationHazard ratioConfoundingMiddle Agedpediatric-onset MS (POMS)Italytherapeutic and managing standardsChild PreschoolDisease ProgressionSettore MED/26 - NeurologiaFemaleDisabled PersonHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentMEDLINEProfile of mood states03 medical and health sciencesYoung AdultmedicineHumansIn patientDisabled PersonsPreschoolpediatric-onset MS (POMS) therapeutic and managing standardsRetrospective StudiesAgedExpanded Disability Status Scalebusiness.industryPediatric-Onset Multiple SclerosisMultiple sclerosisRisk Factormedicine.diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Clinical activity after fingolimod cessation: Disease reactivation or rebound?

2018

Background and purpose There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim was to survey the prevalence of severe reactivation and rebound after discontinuation of fingolimod in a cohort of Italian patients with MS. Methods Patients with relapsing-remitting MS who were treated with fingolimod for at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy were included in the analysis. Results A total of 100 patients who had discontinued fingolimod were included in the study. Fourteen patients (14%…

AdultMalemedicine.medical_specialtyAdolescentDiseaseCohort StudiesMultiple sclerosisImmunosuppressive AgentYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrenceInternal medicineHumansMedicine030212 general & internal medicineFingolimod; Multiple sclerosis; Reactivation; Rebound; Neurology; Neurology (clinical)Natural courseReboundFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseReactivationMagnetic Resonance ImagingFingolimodDiscontinuationItalyWithholding TreatmentNeurologymultiple sclerosiCohortFemaleNeurology (clinical)Cohort StudiebusinessImmunosuppressive Agents030217 neurology & neurosurgeryHumanmedicine.drug
researchProduct

Natalizumab Discontinuation after the 24th Course: Which Is Way? The TY-STOP Study

2013

Multiple SclerosisNatalizumab multiple sclerosisNatalizumabSettore MED/26 - NeurologiaMRi
researchProduct